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Abstract: 
 
Background - Evidence from randomized trials has shown that therapies that lower low-density 
lipoprotein (LDL)-cholesterol and triglycerides reduce coronary artery disease (CAD) risk. 
However, there is still uncertainty regarding their effects on other cardiovascular outcomes. We 
therefore performed a systematic investigation of causal relationships between circulating lipids 
and cardiovascular outcomes using a Mendelian randomization approach. 
Methods - In the primary analysis, we performed two-sample multivariable Mendelian 
randomization using data from participants of European ancestry. We also conducted univariable 
analyses using inverse-variance weighted and robust methods, and gene-specific analyses using 
variants that can be considered as proxies for specific lipid-lowering medications. We obtained 
associations with lipid fractions from the Global Lipids Genetics Consortium, a meta-analysis of 
188,577 participants, and genetic associations with cardiovascular outcomes from 367,703 
participants in UK Biobank. 
Results - For LDL-cholesterol, in addition to the expected positive associations with CAD risk 
(odds ratio per 1 standard deviation increase [OR], 1.45; 95% confidence interval [95%CI] 1.35-
1.57) and other atheromatous outcomes (ischemic cerebrovascular disease and peripheral 
vascular disease), we found independent associations of genetically-predicted LDL-cholesterol 
with abdominal aortic aneurysm (OR 1.75; 95%CI 1.40-2.17) and aortic valve stenosis (OR 1.46; 
95%CI 1.25-1.70). Genetically-predicted triglyceride levels were positively associated with CAD 
(OR 1.25; 95%CI 1.12-1.40), aortic valve stenosis (OR 1.29; 95%CI 1.04-1.61), and 
hypertension (OR 1.17; 95%CI 1.07-1.27), but inversely associated with venous 
thromboembolism (OR 0.79; 95%CI 0.67-0.93) and haemorrhagic stroke (OR 0.78; 95%CI 0.62-
0.98). We also found positive associations of genetically-predicted LDL-cholesterol and 
triglycerides with heart failure that appeared to be mediated by CAD. 
Conclusions - Lowering LDL-cholesterol is likely to prevent abdominal aortic aneurysm and 
aortic stenosis, in addition to CAD and other atheromatous cardiovascular outcomes. Lowering 
triglycerides is likely to prevent CAD and aortic valve stenosis, but may increase 
thromboembolic risk. 
 
 
 
 
 
Key words: lipids; cardiovascular outcomes; etiology; epidemiology; Mendelian randomization 
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Non-standard Abbreviations and Acronyms 
 
APOC3, apolipoprotein C3 
BMI, body mass index 
CAD, coronary artery disease 
HDL-cholesterol, high-density lipoprotein cholesterol 
HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase 
INVENT, International Network against Thrombosis 
LDL-cholesterol, low-density lipoprotein cholesterol 
LDLR, low-density lipoprotein receptor 
LPL, lipoprotein lipase 
MR, Mendelian randomization 
PCSK9, proprotein convertase subtilisin/kexin type 9 
T2D, type-2 diabetes 
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Introduction 
Evidence from randomized trials has shown that therapies that lower low-density lipoprotein 
(LDL)-cholesterol, such as statins, are beneficial for preventing or treating several atheromatous 
diseases such as coronary artery disease (CAD),1 ischaemic stroke,2 and peripheral vascular 
disease,3, 4 as well as both postoperative atrial fibrillation5 and heart failure in the presence of 
underlying CAD.6, 7  However, for other cardiovascular outcomes, such as thromboembolic 
disease,8 haemorrhagic stroke9, 10 and aortic aneurysms,11, 12 the effects of LDL-cholesterol 
lowering are less clear. Recently, the REDUCE-IT trial has shown that therapies that 
predominantly lower triglycerides can reduce major cardiovascular events.13 However, the 
effects of triglyceride lowering on non-atheromatous cardiovascular outcomes are largely 
unknown. 
Although a randomized trial is the gold standard of evidence and is required to 
conclusively establish the effectiveness of a treatment, naturally-occurring genetic variants can 
be used to help predict the outcome of a randomized trial in an approach known as Mendelian 
randomization.14 For example, this approach has been used successfully to validate the effects of 
statins and predict the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 
on CAD risk seen in randomized trials.15, 16 Mendelian randomization investigations have also 
shown positive associations of genetically-predicted LDL-cholesterol with abdominal aortic 
aneurysm,17 ischaemic stroke,18 and aortic stenosis,19 and positive associations of triglycerides 
with CAD.20 While Mendelian randomization makes strong assumptions that the genetic variants 
used in the analysis only influence the outcome via the stated risk factors,21 when both 
approaches can be undertaken Mendelian randomization has generally given results that agree 
with randomized trials.22 
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However, Mendelian randomization approaches have not yet been used to investigate the 
relationship between circulating lipids and some major cardiovascular conditions such as venous 
thromboembolism and heart failure. Additionally, approaches to estimate the independent effects 
of LDL-cholesterol, triglycerides, and high-density lipoprotein (HDL)-cholesterol on 
cardiovascular disease while accounting for genetic pleiotropy have only been performed for a 
limited set of outcomes.17, 19, 20 
Our objective in this paper is to assess which cardiovascular outcomes could be treated 
by lipid-lowering therapies. We performed a systematic Mendelian randomization analysis of 
atheromatous and non-atheromatous cardiovascular disease outcomes. We considered disease 
outcomes in a single dataset (UK Biobank) to ensure a consistent approach to the analysis across 
different outcomes. We carried out polygenic analyses for each of LDL-cholesterol, HDL-
cholesterol, and triglycerides, based on all common genetic variants associated with at least one 
of these risk factors, as well as gene-specific analyses based on variants in or near gene regions 
that mimic specific pharmaceutical interventions. 
 
Methods 
Data availability 
Summary statistics for the genetic associations with lipid fractions were taken from the Global 
Lipids Genetics Consortium, and are available at 
http://csg.sph.umich.edu/willer/public/lipids2013.23, 24 Summary statistics for the genetic 
associations with outcomes were estimated in UK Biobank, and for replication with venous 
thromboembolism in the International Network against Thrombosis (INVENT) Consortium 
(restricting to European descent participants and excluding participants from UK Biobank). 
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Because of the sensitive nature of some of the data collected for this study, requests to access the 
datasets from qualified researchers trained in human subject confidentiality protocols may be 
sent to UK Biobank at https://www.ukbiobank.ac.uk/register-apply,25 and to the INVENT 
Consortium by contacting the senior authors and Co-Conveners of the Consortium, Drs. David-
Alexandre Tregouet and Nicholas L. Smith.26 
UK Biobank and all studies in these consortia were approved by their respective 
institutional review committee and their participants gave informed consent. 
The methods are available as supplemental data. 
 
Results 
Participant characteristics 
Baseline characteristics of the participants in the UK Biobank are provided in Table 1. Around 
46% of participants were men, and the mean age was 57 years. Around 10% were smokers, 93% 
were alcohol drinkers, and 4% had a history of diabetes at baseline.  
Polygenic analyses for all lipid-related variants 
Multivariable Mendelian randomization estimates are displayed graphically in Figure 1 and 
summarized in Supplementary Table S1. Estimates of heterogeneity between the causal estimates 
from different variants are provided in Supplementary Tables S2 and S3, and scatter plots of 
genetic associations for selected risk factor/outcome pairs are provided in Supplementary Figure 
S1. Significant heterogeneity was observed for several outcomes, although this is unsurprising 
given the number of genetic variants included in the analyses. Associations with the positive 
control outcome (CAD) were as expected for LDL-cholesterol and triglycerides. There were no 
associations with the negative control outcome (chronic kidney disease). 
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We found a strong association of genetically-predicted LDL-cholesterol with CAD risk 
(odds ratio per 1 standard deviation increase [OR], 1.45; 95% confidence interval [CI] 1.35-
1.57), which was in the reference range of a previous study.20 The strongest associations by 
magnitude were for abdominal aortic aneurysm (OR 1.75; 95%CI 1.40-2.17), aortic valve 
stenosis (OR 1.46; 95% CI 1.25-1.70), aortic aneurysm (OR 1.43; 95%CI 1.21-1.68), and heart 
failure (OR 1.17; 95%CI 1.06-1.28), which all met our threshold for statistical significance 
(p<0.003). We also observed a significant positive association for the combined outcome of 
ischaemic stroke and transient ischaemic attack (OR 1.14; 95% CI 1.04-1.24). We saw positive 
associations at a nominal significance level (0.003 ≤ p < 0.05) for LDL-cholesterol with risk of 
transient ischaemic attack and peripheral vascular disease. The association with ischaemic stroke 
was in the positive direction but non-significant (OR 1.10; 95% CI 0.98-1.23). 
Genetically-predicted triglyceride levels were strongly associated with increased risk of 
CAD, consistent with previous results,20 as well as with increased risk of hypertension (OR 1.17; 
95%CI 1.07-1.27). Positive nominal associations were noted also for aortic valve stenosis and 
heart failure. A nominally-significant inverse association was observed with haemorrhagic 
stroke, in particular with intracerebral haemorrhage (OR 0.65; 95%CI 0.49-0.86). Inverse 
nominal associations were observed for triglycerides with all of the thromboembolic diseases we 
analysed: deep vein thrombosis (OR 0.78; 95%CI 0.65-0.93), pulmonary embolism (OR 0.78; 
95%CI 0.64-0.96), and any venous thromboembolism (OR 0.79; 95%CI 0.67-0.93). A similar 
association with venous thromboembolism was estimated in a separate sample of 129,002 
individuals of European ancestry from the INVENT consortium (OR 0.84; 95%CI 0.70-1.01, 
p=0.057) (Table 2). Genetically-predicted HDL-cholesterol was nominally associated with lower 
risk of coronary heart disease (OR 0.91; 95%CI 0.83-1.00) and hypertension, and more strongly 
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inversely associated with abdominal aortic aneurysm (OR 0.65; 95%CI 0.51-0.85) and 
intracerebral haemorrhage (OR 0.65; 95%CI 0.51-0.82). In exploratory analyses to validate these 
findings, genetically-predicted triglyceride levels were positively associated with tissue-type 
plasminogen activator, but not with platelet count (Supplementary Table S4). Positive 
associations were observed between genetically-predicted triglycerides and both systolic and 
diastolic blood pressure, whereas inverse associations with HDL-cholesterol were not replicated 
(Supplementary Table S5). 
Univariable Mendelian randomization estimates for each lipid risk factor in turn are 
displayed in Supplementary Figures S2-S4 and summarized in Supplementary Tables S6-S8. 
Similar results were generally obtained from each of the univariable methods as for the 
multivariable methods, although confidence intervals were slightly wider in some cases, 
especially for the MR-Egger method. The association between HDL-cholesterol and CAD 
became null in MR-Egger regression (OR 0.99; 95%CI 0.83-1.19). Similarly, the associations of 
triglycerides with haemorrhagic stroke and its subtypes attenuated to the null in almost all 
univariable analyses (Supplementary Table S8). Another notable difference was a positive 
association of genetically-predicted triglycerides with increased aortic aneurysm risk, 
particularly for abdominal aortic aneurysm. While the association with aortic aneurysm was not 
strongly apparent in the multivariable analysis, it was evident for each of the univariable analysis 
methods. 
We also assessed whether the associations of genetically-predicted lipids with outcomes 
that are comorbid with CAD (e.g. heart failure) may be mediated via CAD, and similarly for 
outcomes that are comorbid with type 2 diabetes (T2D), e.g. hypertension. On adjustment for 
CAD risk (Table 3), the associations of genetically-predicted LDL-cholesterol and triglycerides 
D
ow
nloaded from
 http://ahajournals.org by on November 28, 2019
9 
with heart failure attenuated sharply, suggesting that their effects on heart failure might be 
mediated via CAD. As a negative control, we also performed the same analysis for abdominal 
aortic aneurysm. The association with genetically-predicted LDL-cholesterol attenuated slightly, 
but was still clearly positive. We also performed multivariable Mendelian randomization 
analyses excluding participants with CAD for heart failure (2383 remaining cases). This analysis 
gave null estimates for all lipid fractions (Supplementary Table S9). This suggests that LDL-
cholesterol is unlikely to be a causal risk factor for heart failure where there is no comorbidity 
with CAD. On adjustment for body mass index (BMI) and T2D (Supplementary Table S10), 
associations between lipids and hypertension, abdominal aortic aneurysm, and haemorrhagic 
stroke did not change substantially compared to unadjusted analyses, suggesting that neither 
BMI nor T2D is likely to mediate the effects of lipids on these outcomes. While adjusting for 
heart failure, heart failure was strongly associated with venous thromboembolism, but 
associations between lipids and venous thromboembolism did not change markedly 
(Supplementary Table S10). This confirms that heart failure is an independent risk factor for 
venous thromboembolism but suggests it is unlikely to mediate the association between 
triglycerides and venous thromboembolism.  
Gene-specific analyses for drug proxy variants 
Mendelian randomization estimates for specific gene regions are displayed graphically in Figure 
2 and summarized in Supplementary Tables S11-S12. All the gene regions analysed showed 
clear associations with CAD risk, confirming their involvement in cardiovascular disease 
aetiology and the relevance of existing and proposed lipid-lowering therapies for CAD risk 
reduction. 
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Results for the low-density lipoprotein receptor (LDLR) gene regions, and to a lesser 
extent for 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and PCSK9, were similar to 
those for LDL-cholesterol in the polygenic analyses, although with wider confidence intervals. 
Significant positive associations were obtained for LDLR with aortic and abdominal aortic 
aneurysm, venous thromboembolism, aortic valve stenosis, and heart failure, and an inverse 
association was observed for subarachnoid haemorrhage. Variants in the HMGCR gene region 
were inversely associated with intracerebral haemorrhage (p=0.022). Results for apolipoprotein 
C3 (APOC3) and lipoprotein lipase (LPL) followed a pattern more similar to the analysis for 
triglycerides, showing inverse associations with thromboembolic diseases (p=0.007 for APOC3, 
p=0.089 for LPL for any venous thromboembolism). In both regions, associations with aortic 
aneurysm, aortic valve stenosis and hypertension were all positive. Additionally, variants in the 
LPL region were also positively associated with all ischaemic cerebrovascular diseases. 
 
Discussion 
In this study, we assessed the causal role of three major lipid fractions for a range of 
cardiovascular diseases in a large population-based cohort using the principle of Mendelian 
randomization while accounting for genetic pleiotropy between the lipid measures. Our most 
notable findings were the associations between genetically-predicted triglycerides and decreased 
risk of thromboembolic diseases both in polygenic analyses and in gene-specific analyses for the 
APOC3 gene region, suggesting that reducing triglycerides may increase risk for venous 
thromboembolism. Additionally, as summarized in Supplementary Table S13, we found: 1) 
evidence supporting the current understanding of the aetiology of CAD, suggesting independent 
causal roles for LDL-cholesterol and triglycerides, both in the polygenic analyses and for all the 
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drug-related gene-specific analyses20, 27 2) positive associations of genetically-predicted LDL-
cholesterol with abdominal aortic aneurysm and aortic valve stenosis, as well as atheromatous 
cardiovascular outcomes that are already addressed in clinical guidelines (e.g. peripheral 
vascular disease and the combined outcome of ischaemic stroke and transient ischaemic attack); 
3) positive associations of genetically-predicted LDL-cholesterol and triglycerides with heart 
failure that appear to be mediated by CAD; 4) associations between genetically-predicted 
triglycerides and increased risk of aortic stenosis and hypertension; and 5) inverse associations 
between genetically-predicted HDL-cholesterol and abdominal aortic aneurysm and 
haemorrhagic stroke (in particular, intracerebral haemorrhage) that appear to be independent of 
BMI/T2D. 
The importance of these findings is threefold. Firstly, they help us to better understand 
the aetiology and pathophysiology of common cardiovascular outcomes, and so to identify 
additional potential indications for lipid-lowering therapies. Secondly, association estimates 
provided in this paper can inform calculations on the risk-benefit and cost-benefit of these 
therapies. Thirdly, these findings can aid identification of which patients would most benefit 
from (or should avoid) lipid-lowering therapies. 
Genetic predisposition to lower triglycerides was associated with an increased risk of 
thromboembolic diseases. In contrast, previous observational evidence did not suggest an 
association between triglycerides and venous thrombosis,28, 29 although other lipid measures (in 
particular apolipoprotein B and lipoprotein(a)) were inversely associated with venous thrombosis 
mortality in a meta-analysis of over 700,000 participants from the Emerging Risk Factors 
Collaboration.29 Our result was consistent across 3 of the 4 Mendelian randomization methods 
and was replicated using data from the INVENT collaboration, an independent data source for 
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genetic associations with the outcome. Associations with thromboembolic outcomes using the 
MR-Egger method were slightly attenuated and compatible with the null, raising the possibility 
of unmeasured genetic pleiotropy, although this method generally has lower power compared to 
the conventional inverse-variance weighted method.30 Variants in the APOC3 gene region were 
associated with thromboembolic events, suggesting that lowering triglyceride levels via 
intervening on this pathway may increase thromboembolism risk. Additionally, the positive 
genetic association between triglycerides and tissue-type plasminogen activator reported here 
confirms the findings of a previous observational study among 1227 men free of coronary heart 
disease.31 However, genetically-predicted triglycerides were not associated with platelet count. 
This is in contrast to the APPROACH trial, in which thrombocytopenia led to excess early 
terminations among patients with familial chylomicronaemia32 but in line with (i) two other trials 
of APOC3 inhibitors33, 34 and (ii) with the fluctuations in platelet counts (both thrombocytopenia 
and thrombocytosis) noted in an observational study of 86 patients with familial 
chylomicronaemia.35 Further investigation is needed to confirm the unexpected genetic 
association of triglycerides with venous thromboembolism. 
Both the positive association between genetic predictors of LDL-cholesterol and 
abdominal aortic aneurysm, and the inverse association for HDL-cholesterol, replicate a previous 
Mendelian randomization study which did not include UK Biobank participants.17 This evidence 
is complemented by a randomized trial that has shown benefit from screening and treating 
abdominal aortic aneurysm using various interventions including statins.11 No significant 
association was seen with thoracic aortic aneurysm, in line with the different pathophysiology of 
the two disease subtypes.36 Overall, these findings provide further support to the hypothesis that 
increased LDL-cholesterol has deleterious effects on abdominal aortic aneurysm, and suggest 
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that LDL-cholesterol lowering therapies may be beneficial in preventing abdominal aortic 
aneurysm. 
Similarly, the positive association between genetically-predicted LDL-cholesterol and 
aortic valve stenosis replicates a previous Mendelian randomization study.19 We also 
demonstrated a positive association for triglycerides, in line with the previous study (although 
their result did not achieve conventional levels of statistical significance). Our association was 
robust to all sensitivity analyses and evidenced in gene-specific analyses for both the APOC3 and 
LPL loci. These findings are consistent with previous observational and pathological studies 
suggesting a role of atherosclerotic processes in early valve lesions37, 38 whereas clinical trials 
showed no benefit from LDL-cholesterol lowering via statins on aortic stenosis progression.39 
Taken together, this suggests that increased LDL-cholesterol and triglycerides may facilitate 
initiation of early lesions, but that lipid-lowering therapies may be ineffective in preventing the 
progression of aortic stenosis. 
CAD is a well-known risk factor for heart failure,40 as myocardial ischaemic damage 
reduces myocardial contractility and ventricular function. Associations of heart failure with 
genetically-predicted LDL-cholesterol and triglycerides disappeared after adjusting for CAD. 
The association was also absent when omitting participants with a CAD diagnosis from analyses. 
In contrast, associations with abdominal aortic aneurysm attenuated only slightly after 
adjustment for CAD. Overall, these results suggest that lipid-lowering therapies are only likely to 
influence risk of heart failure via their effects on CAD. 
Our analyses also identified inverse associations of genetically-predicted HDL-C and 
triglyceride levels with risk of intracerebral haemorrhage (albeit the latter association was not 
robust to most sensitivity analyses), consistent with a recent observational analysis for 
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triglycerides.41 Furthermore, we identified a detrimental effect of HMGCR inhibition on 
intracerebral haemorrhage risk, in keeping with a large randomized trial of atorvastatin in 
patients with recent transient ischaemic attack or stroke, which found statin therapy to lower risk 
of major cardiovascular events but increase the risk of haemorrhagic stroke.42 However, this 
finding has not been replicated in large meta-analyses.43 The mechanism relating lipid traits with 
risk of intracerebral haemorrhage requires further exploration. 
Finally, the inverse association between HDL-cholesterol and CAD was only nominally 
significant in the main multivariable analyses but became null with MR-Egger regression, 
suggesting that HDL-cholesterol is unlikely to be a causal risk factor for CAD. 
Our investigation has both strengths and limitations. The large sample size of over 
360,000 participants and the broad set of outcomes analysed render this one of the most 
comprehensive Mendelian randomization analyses on cardiovascular disease conducted to date. 
Availability of multiple cardiovascular conditions within the same study enabled cross-
comparisons between diseases, and enabled us to perform adjusted analyses in the same 
participants and to assess mediation of causal effects. This investigation has a number of 
limitations. Lack of publicly-available summary data from external datasets prevented us from 
performing replication analyses for some associations, e.g. those for heart failure. This design 
still allows sensitivity analyses such as MR-Egger and the weighted median estimator which 
enabled us to investigate and account for the possible presence of genetic pleiotropy, and gene-
specific analyses that are less likely to be influenced by pleiotropy as they only include variants 
from a single gene region where the function is well-known. Significant heterogeneity was 
observed in the polygenic analysis for several outcomes, suggesting that some variants may have 
pleiotropic effects. Additionally, this investigation was conducted in UK-based middle- to late-
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aged participants of European ancestries. While this is recommended for Mendelian 
randomization to ensure that genetic associations are not influenced by population stratification, 
it means that results may not be generalizable to other ethnicities or nationalities. 
In conclusion, multivariable Mendelian randomization analyses accounting for lipid-
related genetic pleiotropy support the hypothesis that circulating lipids have causal effects on a 
wide range of cardiovascular diseases. Interventions that lower LDL-cholesterol are likely to be 
beneficial in preventing aortic aneurysm and aortic stenosis in addition to several other 
atheromatous diseases. Triglyceride lowering treatments are likely to be beneficial in preventing 
coronary artery disease and aortic valve stenosis, but caution is needed due to the possibility of 
increased risk of venous thromboembolism. 
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Table 1: Baseline characteristics of UK Biobank participants included in this study and numbers 
of outcome events 
 
Characteristic Mean (SD) or N (%) 
Sample size 367,703 (100) 
Male 168,799 (45.9) 
Age at baseline 57.2 (8.1) 
Body mass index 27.3 (4.8) 
Systolic blood pressure 137.6 (18.6) 
Diastolic blood pressure 82.0 (10.1) 
Smoking status (current / ex / never)* 37,866 (10.3) / 185,704 (50.5) / 143,777 (39.1) 
Alcohol status (current / ex / never)* 342,797 (93.2) / 12,732 (3.5) / 11,646 (3.2) 
History of type 2 diabetes 15,834 (4.3) 
Coronary Artery Disease 29,278 (8.0) 
Ischaemic Cerebrovascular Event (all) 8084 (2.2) 
 - Ischaemic Stroke 4602 (1.3) 
 - Transient Ischaemic Attack 3962 (1.1) 
Haemorrhagic Stroke (all) 1981 (0.5) 
 - Intracerebral Haemorrhage 1064 (0.3) 
 - Subarachnoid Haemorrhage 1084 (0.3) 
Aortic Aneurysm (all) 1849 (0.5) 
 - Abdominal Aortic Aneurysm 1094 (0.3) 
 - Thoracic Aortic Aneurysm 347 (0.1) 
Venous Thromboembolism (all) 14,097 (3.8) 
 - Deep Vein Thrombosis 9454 (2.6) 
 - Pulmonary Embolism 6148 (1.7) 
Hypertension 125,846 (34.2) 
Peripheral Vascular Disease 3415 (0.9) 
Aortic Valve Stenosis 2244 (0.6) 
Atrial Fibrillation 16,945 (4.6) 
Heart Failure 6712 (1.8) 
Chronic Kidney Disease 6321 (1.7) 
 
* Excluding 356 participants with smoking status absent and 528 participants with alcohol 
consumption status absent 
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Table 2: Replication and meta-analysis of the association between genetically-predicted triglycerides and risk of venous 
thromboembolism in the INVENT consortium. 
 
Venous thromboembolism N events / participants HDL-cholesterol LDL-cholesterol Triglycerides 
UK Biobank 14,097 / 367,703 0.94 
(0.82-1.08) 
1.03 
(0.92-1.16) 
0.79 
(0.67-0.93)* 
INVENT 15,572 / 129,002 1.03 
(0.89-1.20) 
1.07 
(0.94-1.21) 
0.84 
(0.70-1.01) 
UK Biobank + INVENT 29,669 / 496,705 0.98 
(0.86-1.12) 
1.05 
(0.94-1.17) 
0.81 
(0.69-0.95)* 
 
*: p < 0.05 †: p < 0.003 ‡: p <10-8 
All estimates are odds ratios estimated using multivariable inverse-variance weighted Mendelian randomization accounting for lipid-
related genetic pleiotropy and between-variant heterogeneity (random-effects analyses). 
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Table 3: Multivariable Mendelian randomization estimates (odds ratio with 95% confidence interval) for heart failure without and 
with adjustment for coronary artery disease (CAD). Analyses were also performed for abdominal aortic aneurysm as a negative 
control. 
 
Heart failure HDL-cholesterol LDL-cholesterol Triglycerides CAD 
Without adjustment 0.97 
(0.87-1.08) 
1.17 
(1.06-1.28)† 
1.19 
(1.04-1.37)* - 
With adjustment 1.02 
(0.92-1.13) 
0.95 
(0.85-1.06) 
1.06 
(0.93-1.20) 
1.73 
(1.47-2.04)‡ 
     
Abdominal aortic 
aneurysm 
HDL-cholesterol LDL-cholesterol Triglycerides CAD 
Without adjustment 0.65 
(0.51-0.85)† 
1.75 
(1.40-2.17)† 
0.94 
(0.68-1.28) 
- 
With adjustment 0.69 
(0.53-0.88)† 
1.46 
(1.12-1.91)† 
0.84 
(0.61-1.16) 
1.60 
(1.06-2.42)* 
 
*: p < 0.05 †: p < 0.003 ‡: p <10-8 
The CAD column indicates the association between genetically-predicted coronary artery disease and the outcome of interest (i.e. 
heart failure or abdominal aortic aneurysm) while accounting for the genetic associations of the lipid fractions in a multivariable 
analysis. If the regression coefficients for the lipid measurements remain unchanged on adjustment for CAD, then the effects of lipids 
on the outcome do not operate via CAD. If the regression coefficients attenuate to the null, then the effects of lipids on the outcome 
are entirely mediated via CAD. 
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Figure Legends: 
 
Figure 1: Multivariable Mendelian randomization estimates (odds ratio with 95% confidence 
interval per 1 standard deviation increase in lipid fraction) from polygenic analyses including all 
lipid-associated variants 
 
Figure 2: Univariable Mendelian randomization estimates (odds ratio with 95% confidence 
interval per 1 standard deviation increase in lipid fraction) for variants in specific gene regions. 
Estimates are scaled to a unit standard deviation increase in LDL-cholesterol for the HMGCR, 
PCSK9, and LDLR regions, and to a standard deviation increase in triglycerides for the APOC3 
and LPL regions. 
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